vs

Side-by-side financial comparison of Cellectis S.A. (CLLS) and TECHPRECISION CORP (TPCS). Click either name above to swap in a different company.

Cellectis S.A. is the larger business by last-quarter revenue ($9.5M vs $7.1M, roughly 1.3× TECHPRECISION CORP). TECHPRECISION CORP runs the higher net margin — -20.8% vs -265.9%, a 245.1% gap on every dollar of revenue. On growth, Cellectis S.A. posted the faster year-over-year revenue change (375.0% vs -6.9%). Cellectis S.A. produced more free cash flow last quarter ($27.6M vs $-827.0K).

Cellectis is a French biopharmaceutical company. It develops genome-edited chimeric antigen receptor T-cell technologies for cancer immunotherapy. It has offices in Paris, New York City, and Raleigh, North Carolina.

TechPrecision Corp is a manufacturer of custom high-precision metal fabricated components and integrated systems, serving aerospace, defense, medical technology, renewable energy, and industrial end markets primarily across North America and Europe. It specializes in producing tight-tolerance, mission-critical parts that adhere to rigorous industry quality requirements.

CLLS vs TPCS — Head-to-Head

Bigger by revenue
CLLS
CLLS
1.3× larger
CLLS
$9.5M
$7.1M
TPCS
Growing faster (revenue YoY)
CLLS
CLLS
+381.9% gap
CLLS
375.0%
-6.9%
TPCS
Higher net margin
TPCS
TPCS
245.1% more per $
TPCS
-20.8%
-265.9%
CLLS
More free cash flow
CLLS
CLLS
$28.4M more FCF
CLLS
$27.6M
$-827.0K
TPCS

Income Statement — Q2 FY2024 vs Q3 FY2026

Metric
CLLS
CLLS
TPCS
TPCS
Revenue
$9.5M
$7.1M
Net Profit
$-25.3M
$-1.5M
Gross Margin
5.4%
Operating Margin
-181.1%
-19.1%
Net Margin
-265.9%
-20.8%
Revenue YoY
375.0%
-6.9%
Net Profit YoY
-51.9%
-84.4%
EPS (diluted)
$-0.28
$-0.15

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
CLLS
CLLS
TPCS
TPCS
Q4 25
$7.1M
Q3 25
$9.1M
Q2 25
$7.4M
Q1 25
$9.5M
Q4 24
$7.6M
Q3 24
$8.9M
Q2 24
$9.5M
$8.0M
Q1 24
$8.6M
Net Profit
CLLS
CLLS
TPCS
TPCS
Q4 25
$-1.5M
Q3 25
$825.0K
Q2 25
$-597.0K
Q1 25
$112.0K
Q4 24
$-799.0K
Q3 24
$-601.0K
Q2 24
$-25.3M
$-1.5M
Q1 24
$-5.1M
Gross Margin
CLLS
CLLS
TPCS
TPCS
Q4 25
5.4%
Q3 25
27.1%
Q2 25
14.0%
Q1 25
22.0%
Q4 24
13.0%
Q3 24
11.3%
Q2 24
3.0%
Q1 24
14.3%
Operating Margin
CLLS
CLLS
TPCS
TPCS
Q4 25
-19.1%
Q3 25
10.4%
Q2 25
-6.3%
Q1 25
3.9%
Q4 24
-9.1%
Q3 24
-5.5%
Q2 24
-181.1%
-16.8%
Q1 24
-28.6%
Net Margin
CLLS
CLLS
TPCS
TPCS
Q4 25
-20.8%
Q3 25
9.1%
Q2 25
-8.1%
Q1 25
1.2%
Q4 24
-10.5%
Q3 24
-6.7%
Q2 24
-265.9%
-18.3%
Q1 24
-59.5%
EPS (diluted)
CLLS
CLLS
TPCS
TPCS
Q4 25
$-0.15
Q3 25
$0.08
Q2 25
$-0.06
Q1 25
$0.01
Q4 24
$-0.08
Q3 24
$-0.06
Q2 24
$-0.28
$-0.16
Q1 24
$-0.59

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
CLLS
CLLS
TPCS
TPCS
Cash + ST InvestmentsLiquidity on hand
$149.0M
$50.0K
Total DebtLower is stronger
Stockholders' EquityBook value
$148.6M
$8.0M
Total Assets
$407.1M
$32.8M
Debt / EquityLower = less leverage

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
CLLS
CLLS
TPCS
TPCS
Q4 25
$50.0K
Q3 25
$220.0K
Q2 25
$143.0K
Q1 25
$195.0K
Q4 24
$165.0K
Q3 24
$132.0K
Q2 24
$149.0M
$44.8K
Q1 24
$138.0K
Total Debt
CLLS
CLLS
TPCS
TPCS
Q4 25
Q3 25
Q2 25
Q1 25
$3.0K
Q4 24
$19.0K
Q3 24
Q2 24
Q1 24
Stockholders' Equity
CLLS
CLLS
TPCS
TPCS
Q4 25
$8.0M
Q3 25
$9.1M
Q2 25
$8.2M
Q1 25
$8.7M
Q4 24
$8.1M
Q3 24
$8.9M
Q2 24
$148.6M
$7.9M
Q1 24
$7.8M
Total Assets
CLLS
CLLS
TPCS
TPCS
Q4 25
$32.8M
Q3 25
$33.8M
Q2 25
$32.1M
Q1 25
$33.5M
Q4 24
$32.2M
Q3 24
$35.0M
Q2 24
$407.1M
$35.7M
Q1 24
$34.7M
Debt / Equity
CLLS
CLLS
TPCS
TPCS
Q4 25
Q3 25
Q2 25
Q1 25
0.00×
Q4 24
0.00×
Q3 24
Q2 24
Q1 24

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
CLLS
CLLS
TPCS
TPCS
Operating Cash FlowLast quarter
$28.9M
$183.0K
Free Cash FlowOCF − Capex
$27.6M
$-827.0K
FCF MarginFCF / Revenue
290.5%
-11.7%
Capex IntensityCapex / Revenue
13.2%
14.2%
Cash ConversionOCF / Net Profit
TTM Free Cash FlowTrailing 4 quarters
$-4.4M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
CLLS
CLLS
TPCS
TPCS
Q4 25
$183.0K
Q3 25
$-1.1M
Q2 25
$646.0K
Q1 25
$396.0K
Q4 24
$-570.0K
Q3 24
$-532.0K
Q2 24
$28.9M
$107.0K
Q1 24
$-452.0K
Free Cash Flow
CLLS
CLLS
TPCS
TPCS
Q4 25
$-827.0K
Q3 25
$-2.1M
Q2 25
$-604.0K
Q1 25
$-930.0K
Q4 24
$-1.7M
Q3 24
$-2.0M
Q2 24
$27.6M
$-94.0K
Q1 24
$-900.0K
FCF Margin
CLLS
CLLS
TPCS
TPCS
Q4 25
-11.7%
Q3 25
-22.9%
Q2 25
-8.2%
Q1 25
-9.8%
Q4 24
-22.9%
Q3 24
-21.8%
Q2 24
290.5%
-1.2%
Q1 24
-10.5%
Capex Intensity
CLLS
CLLS
TPCS
TPCS
Q4 25
14.2%
Q3 25
11.0%
Q2 25
16.9%
Q1 25
14.0%
Q4 24
15.4%
Q3 24
15.9%
Q2 24
13.2%
2.5%
Q1 24
5.2%
Cash Conversion
CLLS
CLLS
TPCS
TPCS
Q4 25
Q3 25
-1.31×
Q2 25
Q1 25
3.54×
Q4 24
Q3 24
Q2 24
Q1 24

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

CLLS
CLLS

Segment breakdown not available.

TPCS
TPCS

Defense$6.7M94%
Other$410.0K6%

Related Comparisons